Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Vericel Corporation
(NQ:
VCEL
)
41.18
-0.48 (-1.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vericel Corporation
< Previous
1
2
3
4
5
Next >
Earnings Scheduled For February 23, 2023
February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Via
Benzinga
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
February 09, 2023
From
Vericel Corporation
Via
GlobeNewswire
Analyst Ratings for Vericel
January 27, 2023
Via
Benzinga
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
January 25, 2023
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.
Via
Benzinga
What's Going On With Vericel Shares Trading Higher
January 10, 2023
Vericel Corp (NASDAQ: VCEL) shares are trading higher by 13.63% to $27.10 Tuesday after the company reported preliminary FY22 revenue results. What Else?
Via
Benzinga
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
January 10, 2023
From
Vericel Corporation
Via
GlobeNewswire
FDA Approves MediWound's NexoBrid For Burn Treatment
December 30, 2022
Via
Benzinga
Looking Into Vericel's Return On Capital Employed
December 14, 2022
Via
Benzinga
Vericel: Q2 Earnings Insights
August 03, 2022
Vericel (NASDAQ:VCEL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 10, 2023
Gainers
Via
Benzinga
Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
January 04, 2023
From
Vericel Corporation
Via
GlobeNewswire
Vericel: Q1 Earnings Insights
May 04, 2022
Vericel (NASDAQ:VCEL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
December 29, 2022
From
MediWound Ltd.
Via
GlobeNewswire
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
December 29, 2022
From
Vericel Corporation
Via
GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
November 15, 2022
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END
Via
FinancialNewsMedia
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
November 11, 2022
Gainers
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
November 10, 2022
Upgrades
Via
Benzinga
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
November 10, 2022
From
Vericel Corporation
Via
GlobeNewswire
Vericel Reports Third Quarter 2022 Financial Results
November 09, 2022
From
Vericel Corporation
Via
GlobeNewswire
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
November 10, 2022
Gainers
Via
Benzinga
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
October 26, 2022
From
Vericel Corporation
Via
GlobeNewswire
FDA Accepts MediWound's Refiling For Severe Thermal Burns Therapy For Review
August 03, 2022
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ: MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal...
Via
Benzinga
Vericel Earnings Perspective: Return On Capital Employed
May 20, 2022
Benzinga Pro data, Vericel (NASDAQ:VCEL) reported Q1 sales of $36.07 million. Earnings fell to a loss of $7.09 million, resulting in a 256.4% decrease from last quarter. Vericel earned $4.53 million,...
Via
Benzinga
Earnings Scheduled For May 4, 2022
May 04, 2022
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
June 14, 2022
On Tuesday, 951 companies hit new 52-week lows.
Via
Benzinga
Vericel Q1 2022 Earnings Conference Call On May 4, 2022 At 08:30 AM ET
April 25, 2022
Vericel (NASDAQ:VCEL) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Vericel (VCEL) Conference Call Follow this link to access the live...
Via
Benzinga
88 Biggest Movers From Yesterday
February 25, 2022
Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million private placement. Indonesia Energy Corporation...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
February 24, 2022
Gainers Lantheus Holdings (NASDAQ:LNTH) stock rose 33.3% to $38.46 during Thursday's regular session. The current volume of 3.4 million shares is 876.7% of Lantheus...
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.